GlassScriptPhysician profile
Nicolas John Ripp
NPI 1740547744
$3,013.47
in general payments reported to CMS, 2019-2025
25 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $90.28 · 2021: $227 · 2022: $693 · 2023: $617 · 2024: $794 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $661.98 | 2019-2024 | Jornay Pm |
| Corium, LLC | $631.66 | 2021-2024 | Azstarys |
| Glaxosmithkline, LLC. | $364.64 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $221.45 | 2019-2024 | |
| Sanofi Pasteur INC. | $202.15 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $114.28 | 2019-2024 | Relexxii |
| Merck Sharp & Dohme LLC | $104.55 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Neos Therapeutics, LP | $92.80 | 2019-2020 | |
| Tris Pharma INC | $88.49 | 2019-2021 | |
| Seqirus USA INC | $67.69 | 2022-2025 | Flucelvax |
| Cranial Technologies, INC | $64.63 | 2022-2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $63.15 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $48.73 | 2023 | |
| Verrica Pharmaceuticals INC. | $44.39 | 2024-2025 | Ycanth |
| Adlon Therapeutics L.P. | $34.84 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $23.32 | 2025 | Jornay Pm |
| Alk-Abello, INC | $23.14 | 2025 | Neffy |
| Sobi, INC | $22.59 | 2021 | |
| Genentech USA, INC. | $21.47 | 2020 | |
| Nestle Healthcare Nutrition INC. | $20.79 | 2023 | |
| Mylan Pharmaceuticals INC. | $19.34 | 2019 | |
| Abbvie INC. | $18.69 | 2023 | Lo Loestrin Fe |
| Phadia US INC. | $17.85 | 2023 | Immunocap |
| Mission Pharmacal Company | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Ripp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.